Back to the list
Congress: ECR25
Poster Number: C-23631
Type: Poster: EPOS Radiologist (educational)
Authorblock: F. Delaney1, R. Chung1, A. Sweeney2, M. A. Blake1; 1Boston, MA/US, 2Brighton, MA/US
Disclosures:
Francis Delaney: Nothing to disclose
Ryan Chung: Nothing to disclose
Ann Sweeney: Nothing to disclose
Michael Austin Blake: Nothing to disclose
Keywords: Abdomen, Oncology, Retroperitoneum, CT, MR, Imaging sequences, Congenital, Endocrine disorders, Neoplasia
References
  1. Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90-114.
  2. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018;51:68-73.
  3. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459-66.
  4. Motta-Ramirez GA, Remer EM, Herts BR, Gill IS, Hamrahian AH. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185(3):684-8.
  5. De Filpo G, Cantini G, Rastrelli G, Vannini G, Ercolino T, Luconi M, et al. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience. J Endocrinol Invest. 2022;45(1):149-57.
  6. Amin MB, Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. Eighth edition. ed. Switzerland: Springer; 2017. xvii, 1024 pages p.
  7. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717-25.
  8. Papathomas TG, Suurd DPD, Pacak K, Tischler AS, Vriens MR, Lam AK, et al. What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas? Endocr Pathol. 2021;32(1):134-53.
  9. Gimenez-Roqueplo AP, Robledo M, Dahia PLM. Update on the genetics of paragangliomas. Endocr Relat Cancer. 2023;30(4).
  10. Withey SJ, Perrio S, Christodoulou D, Izatt L, Carroll P, Velusamy A, et al. Imaging Features of Succinate Dehydrogenase-deficient Pheochromocytoma-Paraganglioma Syndromes. Radiographics. 2019;39(5):1393-410.
  11. Chung R, O'Shea A, Sweeney AT, Mercaldo ND, McDermott S, Blake MA. Hereditary and Sporadic Pheochromocytoma: Comparison of Imaging, Clinical, and Laboratory Features. AJR Am J Roentgenol. 2022;219(1):97-109.
  12. Sweeney A, Srivoleti P, Blake M. Management of the patient with bilateral adrenal nodules. Journal of Clinical and Translational Endocrinology: Case Reports. 2021. Volume 20. h ttps://doi.org/10.1016/j.jecr.2021.100082.
  13. Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol. 2013;200(2):370-8.
  14. Park BK, Kim CK, Kwon GY, Kim JH. Re-evaluation of pheochromocytomas on delayed contrast-enhanced CT: washout enhancement and other imaging features. Eur Radiol. 2007;17(11):2804-9.
  15. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, et al. Pheochromocytoma: an imaging chameleon. Radiographics. 2004;24 Suppl 1:S87-99.
  16. Blake MA, Krishnamoorthy SK, Boland GW, Sweeney AT, Pitman MB, Harisinghani M, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol. 2003;181(6):1663-8.
  17. Marti JL, Millet J, Sosa JA, Roman SA, Carling T, Udelsman R. Spontaneous adrenal hemorrhage with associated masses: etiology and management in 6 cases and a review of 133 reported cases. World J Surg. 2012;36(1):75-82.
  18. Raja A, Leung K, Stamm M, Girgis S, Low G. Multimodality imaging findings of pheochromocytoma with associated clinical and biochemical features in 53 patients with histologically confirmed tumors. AJR Am J Roentgenol. 2013;201(4):825-33.
  19. Wang K, Tang G, Peng Y, Li C, Fu W, Li R, et al. Adrenal pheochromocytoma: is it all or the tip of the iceberg? Jpn J Radiol. 2022;40(2):120-34.
  20. Gruber LM, Strajina V, Bancos I, Murad MH, Dy BM, Young WF, et al. Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta-analysis. Gland Surg. 2020;9(2):362-71.
  21. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194(6):1450-60.
  22. Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42.
  23. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42.
  24. Kebapci M, Kaya T, Gurbuz E, Adapinar B, Kebapci N, Demirustu C. Differentiation of adrenal adenomas (lipid rich and lipid poor) from nonadenomas by use of washout characteristics on delayed enhanced CT. Abdom Imaging. 2003;28(5):709-15.
  25. Peña CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217(3):798-802.
  26. Kang S, Oh YL, Park SY. Distinguishing pheochromocytoma from adrenal adenoma by using modified computed tomography criteria. Abdom Radiol (NY). 2021;46(3):1082-90.
  27. Buitenwerf E, Korteweg T, Visser A, Haag CMSC, Feelders RA, Timmers HJLM, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol. 2018;178(5):431-7.
  28. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Pheochromocytoma as a frequent false-positive in adrenal washout CT: A systematic review and meta-analysis. Eur Radiol. 2018;28(3):1027-36.
  29. Corwin MT, Badawy M, Caoili EM, Carney BW, Colak C, Elsayes KM, et al. Incidental Adrenal Nodules in Patients Without Known Malignancy: Prevalence of Malignancy and Utility of Washout CT for Characterization-A Multiinstitutional Study. AJR Am J Roentgenol. 2022;219(5):804-12.
  30. Schloetelburg W, Ebert I, Petritsch B, Weng AM, Dischinger U, Kircher S, et al. Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. Eur J Endocrinol. 2021;186(2):183-93.
  31. Corwin MT, Caoili EM, Elsayes KM, Garratt J, Hackett CE, Hudson E, et al. Performance of CT With Adrenal-Washout Protocol in Heterogeneous Adrenal Nodules: A Multiinstitutional Study. AJR Am J Roentgenol. 2024.
  32. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234(2):479-85.
  33. Fonseca EKUN, Ponte MPTR, Yamauchi FI, Baroni RH. The light bulb sign in pheochromocytoma. Abdom Radiol (NY). 2017;42(11):2779.
  34. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD. Comparison of Quantitative MRI and CT Washout Analysis for Differentiation of Adrenal Pheochromocytoma From Adrenal Adenoma. AJR Am J Roentgenol. 2016;206(6):1141-8.
  35. Mody RN, Remer EM, Nikolaidis P, Khatri G, Dogra VS, Ganeshan D, et al. ACR Appropriateness Criteria® Adrenal Mass Evaluation: 2021 Update. J Am Coll Radiol. 2021;18(11S):S251-S67.
  36. Araujo-Castro M, García Centeno R, Robles Lázaro C, Parra Ramírez P, Gracia Gimeno P, Rojas-Marcos PM, et al. Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours. Sci Rep. 2022;12(1):2671.
  37. Inan N, Arslan A, Akansel G, Anik Y, Balci NC, Demirci A. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses. Eur J Radiol. 2008;65(1):154-62.
  38. Rodacki K, Ramalho M, Dale BM, Battisti S, de Campos RO, Giardino A, et al. Combined chemical shift imaging with early dynamic serial gadolinium-enhanced MRI in the characterization of adrenal lesions. AJR Am J Roentgenol. 2014;203(1):99-106.
  39. Becker-Weidman D, Kalb B, Mittal PK, Harri PA, Arif-Tiwari H, Farris AB, et al. Differentiation of lipid-poor adrenal adenomas from non-adenomas with magnetic resonance imaging: Utility of dynamic, contrast enhancement and single-shot T2-weighted sequences. Eur J Radiol. 2015;84(11):2045-51.
  40. Miller FH, Wang Y, McCarthy RJ, Yaghmai V, Merrick L, Larson A, et al. Utility of diffusion-weighted MRI in characterization of adrenal lesions. AJR Am J Roentgenol. 2010;194(2):W179-85.
  41. Tufton N, White G, Drake WM, Sahdev A, Akker SA. Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: A pilot study. Clin Endocrinol (Oxf). 2019;91(1):104-9.
  42. Takano A, Oriuchi N, Tsushima Y, Taketomi-Takahashi A, Nakajima T, Arisaka Y, et al. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann Nucl Med. 2008;22(5):395-401.
  43. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? Radiology. 2004;231(3):711-6.
  44. Sebro R, Aslam R, Muglia VF, Wang ZJ, Westphalen AC. Low yield of chemical shift MRI for characterization of adrenal lesions with high attenuation density on unenhanced CT. Abdom Imaging. 2015;40(2):318-26.
  45. Seo JM, Park BK, Park SY, Kim CK. Characterization of lipid-poor adrenal adenoma: chemical-shift MRI and washout CT. AJR Am J Roentgenol. 2014;202(5):1043-50.
  46. Araujo-Castro M, García Sanz I, Mínguez Ojeda C, Calatayud M, Hanzu FA, Mora M, et al. An Integrated CT and MRI Imaging Model to Differentiate between Adrenal Adenomas and Pheochromocytomas. Cancers (Basel). 2023;15(14).
  47. Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, Baudin E, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17(7):435-44.
GALLERY